This fully funded PhD studentship at the University of Birmingham offers an exciting opportunity to investigate the role of unconventional T cells in immunosurveillance of MGUS (monoclonal gammopathy of uncertain significance) and its progression to multiple myeloma (MM), an incurable plasma cell malignancy. The project aims to clarify how adaptive γδT-cell immunity contributes to the control of preneoplastic conditions and how these mechanisms differ in MM, addressing a key gap in current cancer immunology research.

Students will receive comprehensive training in cellular and molecular immunology, working within the Department of Immunology and Immunotherapy and supported by a supervisory team with internationally recognized expertise in unconventional T cells and myeloma. The research will employ advanced phenotyping techniques such as spectral flow cytometry and multispectral immunofluorescence, alongside cellular assays to assess plasma-cell-specific immune responses. Molecular approaches will be used to characterize γδTCR clonotypes, including single cell PCR, TCR transduction, and reporter assays, with a focus on MHC-independent recognition mechanisms that have broad applicability across patient populations.

The project is designed to provide ample opportunities for high-impact publications and to position graduates for diverse career paths in the rapidly evolving field of immuno-oncology. The studentship is funded by the Medical Research Council for four years and includes a stipend, tuition fees at both home and international rates, a laptop allowance, research training and support grant (RTSG), and travel allowance. Applications are welcomed from home, EU, and international candidates, though international recruitment is capped at 30% of the cohort due to funding stipulations.

Applicants should have a strong academic background in biology, biomedical sciences, immunology, or related disciplines, with laboratory research experience considered advantageous. The application deadline is midday (GMT) on 9 January 2026, and late applications will not be considered. For further details and to access the application form, visit the MRC AIM website. This project offers a unique chance to contribute to cutting-edge cancer immunology research and to develop skills highly valued in both academic and commercial sectors.